Vericel Corporation (VCEL)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Vericel Corporation (VCEL)
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Key Insights
Critical company metrics and information
Share Price
$57.67Market Cap
$2.85 BillionTotal Outstanding Shares
49.36 Million SharesTotal Employees
314Dividend
No dividendIPO Date
February 4, 1997SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.vcel.com
Historical Stock Splits
If you bought 1 share of VCEL before October 16, 2013, you'd have 0.05 shares today.
Execution Date | Split Amount |
---|---|
October 16, 2013 | 1-for-20 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-72.47 Million |
Net Cash Flow | $-13.21 Million |
Net Cash Flow, Continuing | $-13.21 Million |
Net Cash Flow From Operating Activities, Continuing | $46.01 Million |
Net Cash Flow From Financing Activities | $13.25 Million |
Net Cash Flow From Investing Activities | $-72.47 Million |
Net Cash Flow From Operating Activities | $46.01 Million |
Net Cash Flow From Financing Activities, Continuing | $13.25 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Income Tax Expense/Benefit | $1.10 Million |
Diluted Earnings Per Share | $0.08 |
Revenues | $226.84 Million |
Income/Loss From Continuing Operations Before Tax | $4.65 Million |
Net Income/Loss Attributable To Parent | $3.55 Million |
Operating Expenses | $163.34 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Income/Loss From Continuing Operations After Tax | $3.55 Million |
Basic Average Shares | $48.69 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Research and Development | $24.77 Million |
Operating Income/Loss | $-1.23 Million |
Diluted Average Shares | $48.69 Million |
Gross Profit | $162.12 Million |
Cost Of Revenue | $64.73 Million |
Costs And Expenses | $222.20 Million |
Net Income/Loss | $3.55 Million |
Nonoperating Income/Loss | $5.88 Million |
Basic Earnings Per Share | $0.08 |
Benefits Costs and Expenses | $222.20 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss Available To Common Stockholders, Basic | $3.55 Million |
Selling, General, and Administrative Expenses | $138.57 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Assets | $390.40 Million |
Other Current Assets | $174.76 Million |
Equity Attributable To Parent | $257.47 Million |
Other Current Liabilities | $17.38 Million |
Noncurrent Assets | $199.88 Million |
Equity | $257.47 Million |
Wages | $3.09 Million |
Current Assets | $190.52 Million |
Noncurrent Liabilities | $91.59 Million |
Liabilities | $132.93 Million |
Inventory | $15.76 Million |
Accounts Payable | $20.88 Million |
Current Liabilities | $41.35 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Liabilities And Equity | $390.40 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.